{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T16:34:52Z","timestamp":1770568492001,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00228-021-03183-0","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T13:02:44Z","timestamp":1625490164000},"page":"1783-1790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dasiglucagon: an effective medicine for severe hypoglycemia"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-9103","authenticated-orcid":false,"given":"Bo","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaorui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"3183_CR1","doi-asserted-by":"crossref","unstructured":"Beato-V\u00edbora PI, Arroyo-D\u00edez FJ (2019) New uses and formulations of glucagon for hypoglycaemia. Drugs Context 30(8):212599","DOI":"10.7573\/dic.212599"},{"key":"3183_CR2","doi-asserted-by":"crossref","unstructured":"Pearson T (2008) Glucagon as a treatment of severe hypoglycemia: safe and efficacious but underutilized. Diabetes Educ 34(1):128\u201334","DOI":"10.1177\/0145721707312400"},{"issue":"4","key":"3183_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/dom.13941","volume":"22","author":"VT Thieu","year":"2020","unstructured":"Thieu VT, Mitchell BD, Varnado OJ, Frier BM (2020) Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon. Diabetes Obes Metab 22(4):469\u2013479","journal-title":"Diabetes Obes Metab"},{"key":"3183_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/DMSO.S20633","volume":"4","author":"N Kedia","year":"2011","unstructured":"Kedia N (2011) Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Obes 4:337\u2013346","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"3183_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","volume":"7","author":"International Hypoglycaemia Study Group","year":"2019","unstructured":"International Hypoglycaemia Study Group (2019) Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 7(5):385\u2013396","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"3183_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11892-019-1216-4","volume":"19","author":"CP Hawkes","year":"2019","unstructured":"Hawkes CP, De Leon DD, Rickels MR (2019) Novel preparations of glucagon for the prevention and treatment of hypoglycemia. Curr Diab Rep 19(10):97","journal-title":"Curr Diab Rep"},{"key":"3183_CR7","doi-asserted-by":"crossref","unstructured":"Rentzepis PJ et al (2018) Practical ways to achieve targets in diabetes care. 911\u2013915","DOI":"10.1111\/1753-0407.12842"},{"key":"3183_CR8","unstructured":"Zealand Pharma (2021) Dasiglucagon, a novel glucagon analog phase 2 update. Available from: https:\/\/static1.squarespace.com\/static\/58983777d1758e28995640b4\/t\/5912d3251e5b6cb374772105\/1494405933418\/TIDES"},{"issue":"5","key":"3183_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1753-0407.12644","volume":"10","author":"AM Carracher","year":"2018","unstructured":"Carracher AM, Marathe PH, Close KL (2018) International Diabetes Federation 2017. J Diabetes 10(5):353\u2013356","journal-title":"J Diabetes"},{"key":"3183_CR10","unstructured":"FDA approves Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycemia in people with diabetes. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/214231Orig1s000ltr.pdf. Accessed 9\u00a0May\u00a02021"},{"key":"3183_CR11","doi-asserted-by":"crossref","unstructured":"Blair HA (2021) Dasiglucagon: First Approval. Drugs\u00a0","DOI":"10.1007\/s40265-021-01531-z"},{"key":"3183_CR12","doi-asserted-by":"crossref","unstructured":"Macchi F, Wenander C, Lundholt BK (2021) Dasiglucagon is a novel stable glucagon analog with rapid glucose response following subcutaneous injection in hypoglycemic rats.\u00a0Metab Clin Exp\u00a0116","DOI":"10.1016\/j.metabol.2020.154508"},{"key":"3183_CR13","doi-asserted-by":"publisher","unstructured":"Dasiglucagon: l\u00f6sungsstabiles, effektives und sicheres Glucagonanalogon. diabetologie und stoffwechsel\u00a013.03(2018):214\u2013214. https:\/\/www.thieme-connect.de\/products\/ejournals\/abstract\/https:\/\/doi.org\/10.1055\/a-0609-9671. Accessed 9\u00a0May\u00a02021","DOI":"10.1055\/a-0609-9671"},{"issue":"11","key":"3183_CR14","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1080\/14656566.2020.1747432","volume":"21","author":"S Li","year":"2020","unstructured":"Li S, Hu Y, Tan X et al (2020) Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes. Expert Opin Pharmacother 21(11):1311\u20131318","journal-title":"Expert Opin Pharmacother"},{"key":"3183_CR15","unstructured":"Drugs@FDA: FDA-Approved Drugs.\u00a0https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=214231.  Accessed 9\u00a0May 2021"},{"key":"3183_CR16","unstructured":"Full Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214231s000lbl.pdf. Accessed  9 May\u00a02021"},{"issue":"3","key":"3183_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2337\/dc17-1402","volume":"41","author":"U H\u00f6velmann","year":"2018","unstructured":"H\u00f6velmann U, Bysted BV, Mouritzen U et al (2018) Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care 41(3):531\u2013537","journal-title":"Diabetes Care"},{"issue":"3","key":"3183_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/dom.13562","volume":"21","author":"U H\u00f6velmann","year":"2019","unstructured":"H\u00f6velmann U, Olsen MB, Mouritzen U, Lamers D, Kronshage B, Heise T (2019) Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. Diabetes Obes Metab 21(3):601\u2013610","journal-title":"Diabetes Obes Metab"},{"key":"3183_CR19","unstructured":"Pieber T et al (2020) Immunogenicity and other safety parameters following multiple SC doses of dasiglucagon.\u00a0dIabetes Technology & Therapeutics. Vol. 22. 140 Huguenot Street, 3rd Fl, New Rochelle, Ny 10801 Usa: Mary Ann Liebert, Inc"},{"issue":"2","key":"3183_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/dia.2018.0363","volume":"21","author":"JR Castle","year":"2019","unstructured":"Castle JR, Elander M (2019) Long-term safety and tolerability of dasiglucagon, a stable-in-solution glucagon analogue. Diabetes Technol Ther 21(2):94\u201396","journal-title":"Diabetes Technol Ther"},{"key":"3183_CR21","doi-asserted-by":"crossref","unstructured":"Bailey TS et al (2020) 1053-P: dasiglucagon hypopal autoinjector as a fast and effective treatment for severe hypoglycemia: results of a phase 3 trial","DOI":"10.2337\/db20-1053-P"},{"key":"3183_CR22","doi-asserted-by":"crossref","unstructured":"Battelino T et al (2021) Dasiglucagon, a ready-to-use glucagon analog, for rapid and effective treatment of severe hypoglycemia: a phase 3, randomized controlled trial in children with type 1 diabetes.\u00a0Metab Clin Exp\u00a0116","DOI":"10.1016\/j.metabol.2020.154507"},{"key":"3183_CR23","doi-asserted-by":"crossref","unstructured":"Pieber TR, Aronson R, H\u00f6velmann U, Willard J, Plum-M\u00f6rschel L, Knudsen KM, Bandak B, Tehranchi R. Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care. 2021 Apr 21:dc202995.","DOI":"10.2337\/figshare.14207960.v1"},{"key":"3183_CR24","doi-asserted-by":"crossref","unstructured":"Battelino T, Tehranchi R, Bailey T et al (2021) Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: results of a phase 3, randomized controlled trial.\u00a0Pediatr Diabetes","DOI":"10.1111\/pedi.13220"},{"key":"3183_CR25","unstructured":"Feasibility trial testing the bionic pancreas with ZP4207. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02971228. Accessed 9\u00a0May\u00a02021"},{"key":"3183_CR26","doi-asserted-by":"crossref","unstructured":"Castellanos LE, Balliro CA, Sherwood JS et al (2021) Performance of the insulin-only iLet bionic pancreas and the bihormonal iLet using dasiglucagon in adults with type 1 diabetes in a home-use setting.\u00a0Diabetes Care dc201086","DOI":"10.2337\/dc20-1086"},{"key":"3183_CR27","doi-asserted-by":"crossref","unstructured":"Sherwood J et al (2020) 198-OR: individual response of automated glycemic control with the iLet bionic pancreas in the insulin-only vs. bihormonal configuration with the stable glucagon analog dasiglucagon","DOI":"10.2337\/db20-198-OR"},{"key":"3183_CR28","doi-asserted-by":"crossref","unstructured":"Nielsen CK et al (2020) 10-LB: dasiglucagon ameliorates postprandial hypoglycemia after Roux-en-y gastric bypass","DOI":"10.2337\/db20-10-LB"},{"key":"3183_CR29","unstructured":"A trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with T1DM. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03895697. Accessed 9 May\u00a02021"},{"key":"3183_CR30","unstructured":"Low-dose\u2002dasiglucagon\u2002for prevention of insulin-induced hypoglycemia in people with type 1 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04449692. Accessed\u00a09 May 2021"},{"key":"3183_CR31","unstructured":"Open-label trial evaluating efficacy and safety of dasiglucagon in children with congenital hyperinsulinism. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03777176. Accessed 9 May 2021"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03183-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T06:03:28Z","timestamp":1636610608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03183-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3183"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03183-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not include any new research on humans or animals by any author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}